Search

The article explores the association between atopic dermatitis burden, sociodemographic index, and the utilization of biologics like dupilumab and tralokinumab across 50 countries from 2017 to 2022. It highlights disparities in biologic utilization based on countries' economic status, with high-cost barriers limiting access in low-middle and middle-SDI countries. The study suggests that measures to reduce costs and improve access to biologics, such as biosimilars, are needed to address these disparities and improve outcomes in resource-limited settings. [Extracted from the article]